JASCHANDRIA BELL: Open Payments
NPI 1407264989 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,239 in 41 payments from 8 companies in 2025. Trend: 2023 $2,035 · 2024 $639 · 2025 $1,239
Food & beverage: $1,239
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $353 |
| Alkermes, Inc. | 14 | $312 |
| Axsome Therapeutics, Inc. | 2 | $248 |
| E.R. Squibb & Sons, L.L.C. | 6 | $120 |
| Janssen Pharmaceuticals, Inc | 2 | $72 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $71 |
| Vanda Pharmaceuticals Inc. | 2 | $38 |
| Collegium Pharmaceutical, Inc. | 1 | $24 |
Products named: VRAYLAR, Auvelity, ARISTADA, LYBALVI, COBENFY, INVEGA SUSTENNA, CAPLYTA, FANAPT.
Industry payments across LA — which companies pay providers there.
